Fresenius Kabi Oncology Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Fresenius Kabi Oncology Limited Pharmaceutical Export Portfolio Dataset — 16 Products, $117.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Fresenius Kabi Oncology Limited — Pharmaceutical Exporter Profile (2026) | 16 Products, $117.2M Trade | TransData Nexus

Fresenius Kabi Oncology Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $117.2M Total Trade · DGFT Verified

Fresenius Kabi Oncology Limited is an Indian pharmaceutical exporter with a total trade value of $117.2M across 16 products in 3 therapeutic categories. Based on 4,662 verified export shipments from Indian Customs (DGFT) records, Fresenius Kabi Oncology Limited is the #1 Indian exporter in 7 products including Carboplatin, Paclitaxel, Oxaliplatin. Top exports include Carboplatin ($27.5M), Paclitaxel ($25.1M), Oxaliplatin ($16.6M).

Fresenius Kabi Oncology Limited — Export Portfolio & Destination Treemap

Fresenius Kabi Oncology Limited pharmaceutical export portfolio — 16 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Fresenius Kabi Oncology Limited? — Company Overview & Market Position

Fresenius Kabi Oncology Limited, established in 2003, is a wholly owned subsidiary of Fresenius Kabi, a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company is headquartered in Gurugram, Haryana, India, with its registered office located at B-310, Som Datt Chambers-1, Bhikaji Cama Place, New Delhi-110066, India. The Corporate Identification Number (CIN) is U24231DL2003PLC119441. The company employs approximately 1,152 individuals. For more information, visit their official website at www.fresenius-kabi-oncology.com.

What Does Fresenius Kabi Oncology Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Carboplatin$27.5M 2Paclitaxel$25.1M

Product Portfolio — Top 16 by Export Value

Fresenius Kabi Oncology Limited exports 16 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 7 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Carboplatin	Oncology	$27.5M	735	38.8%	1
2	Paclitaxel	Oncology	$25.1M	854	30.2%	1
3	Oxaliplatin	Advanced Oncology	$16.6M	602	35.7%	1
4	Irinotecan	Oncology	$10.4M	670	25.4%	2
5	Pemetrexed	Advanced Oncology	$9.0M	333	31.1%	1
6	Docetaxel	Oncology	$8.4M	356	21.1%	1
7	Gemcitabine	Oncology	$6.9M	339	14.8%	1
8	Doxorubicin	Oncology	$3.1M	143	4.6%	3
9	Cisplatin	Oncology	$2.8M	60	21.5%	1
10	Etoposide	Oncology	$1.9M	126	17.3%	2
11	Cytarabine	Advanced Oncology	$1.8M	98	16.9%	2
12	Epirubicin	Advanced Oncology	$1.1M	42	16.9%	3
13	Bortezomib	Advanced Oncology	$803.7K	99	3.7%	5
14	Methotrexate	Immunosuppressants	$771.5K	101	2.2%	8
15	Busulfan	Advanced Oncology	$627.6K	77	12.7%	3
16	Vinorelbine	Advanced Oncology	$512.3K	27	15.1%	3

Fresenius Kabi Oncology Limited exports 16 pharmaceutical products across 3 therapeutic categories with a total export value of $117.2M. The company is the #1 Indian exporter in 7 products: Carboplatin, Paclitaxel, Oxaliplatin, Pemetrexed, Docetaxel and 2 more. The top category is Oncology (73.4% of portfolio), followed by Advanced Oncology (26.0%), indicating a concentrated portfolio with the top 5 products accounting for 75.6% of total export value.

Fresenius Kabi Oncology Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Fresenius Kabi Oncology Limited operates two primary manufacturing facilities in India. The Baddi plant in Himachal Pradesh specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The Kalyani facility in West Bengal focuses on the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. Both facilities adhere to stringent quality management systems and comply with current Good Manufacturing Practices (cGMP) to ensure the safety and efficacy of their products.

3Key Leadership

The leadership team at Fresenius Kabi Oncology Limited includes:

Mr. Eduardo Ricardo Santos Montanha: Non-Executive Chairman
Mr. Nikhil Kulshreshtha: Head of Legal, Compliance Officer, Company Secretary, and Whole-Time Director since 2007
Mr. Michael Schonhofen: Non-Executive Director since 2008
Mr. Rakesh Bhargava: Non-Executive Director since 2008
Mr. Rajiv Lochan Jain: Non-Executive Independent Director since 2013
Mr. Karsten Peter Lerch: Non-Executive Director since 2018
Mr. Steffen Georg Roser: Non-Executive Director
Ms. Heike Susanne Van Dawen: Non-Executive Director
Mr. Maximilian Alexander Boehmer: Non-Executive Director
Mr. Phaisal Sirisinsuk: Director of Dabur Pharma (Thailand) Company Ltd since 2003

These leaders bring a wealth of experience and expertise to the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Fresenius Kabi Oncology Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Fresenius Kabi Oncology Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its finished pharmaceutical formulations from various regulatory bodies, ensuring compliance with international standards. In the United States, the company has faced regulatory scrutiny, with warning letters issued by the FDA in December 2017 for facilities in Kalyani and Baddi. These letters highlighted violations of current Good Manufacturing Practices (cGMP), leading to corrective actions and improvements in manufacturing processes. Despite these challenges, Fresenius Kabi Oncology Limited continues to supply products to the U.S. market, demonstrating resilience and commitment to quality.

2Emerging Markets

Fresenius Kabi Oncology Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality is endorsed by regulatory authorities such as the Therapeutic Goods Administration (TGA) in Australia, the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the U.S. Food and Drug Administration (FDA). These certifications facilitate access to various markets, enabling the company to provide affordable and effective oncology treatments to a broader patient population.

Fresenius Kabi Oncology Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Fresenius Kabi Oncology Limited's facilities have been subject to inspections by the U.S. Food and Drug Administration (FDA). In May 2017, the FDA inspected the Kalyani facility in West Bengal, leading to a warning letter issued in December 2017. Similarly, the Baddi facility in Himachal Pradesh was inspected in April 2017, resulting in another warning letter in December 2017. These inspections identified violations of current Good Manufacturing Practices (cGMP), prompting the company to implement corrective actions to address the issues raised. Despite these challenges, Fresenius Kabi Oncology Limited continues to supply products to the U.S. market, demonstrating its commitment to compliance and quality.

2WHO & EU GMP

Fresenius Kabi Oncology Limited's manufacturing facilities adhere to stringent quality management systems and comply with current Good Manufacturing Practices (cGMP) as endorsed by regulatory authorities such as the Therapeutic Goods Administration (TGA) in Australia, the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the U.S. Food and Drug Administration (FDA). These certifications facilitate access to various markets, enabling the company to provide affordable and effective oncology treatments to a broader patient population.

Fresenius Kabi Oncology Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Fresenius Kabi Oncology Limited operates in a competitive landscape, with several key players in the oncology generics segment. The company's top competitors include multinational pharmaceutical companies and specialized oncology firms that offer similar product portfolios. Fresenius Kabi Oncology Limited distinguishes itself through its comprehensive product range, including injectables, oral cytotoxics, cytostatics, intermediates, and Active Pharmaceutical Ingredients (APIs). The company's commitment to quality, as endorsed by regulatory authorities such as the Therapeutic Goods Administration (TGA), European Directorate for the Quality of Medicines & HealthCare (EDQM), and U.S. Food and Drug Administration (FDA), further strengthens its position in the market.

2Key Differentiators

Fresenius Kabi Oncology Limited's key differentiators include its comprehensive product portfolio, which spans injectables, oral cytotoxics, cytostatics, intermediates, and Active Pharmaceutical Ingredients (APIs). The company's commitment to quality is demonstrated through adherence to current Good Manufacturing Practices (cGMP) and certifications from regulatory authorities such as the Therapeutic Goods Administration (TGA), European Directorate for the Quality of Medicines & HealthCare (EDQM), and U.S. Food and Drug Administration (FDA). Additionally, the company's global reach and focus on emerging markets enable it to provide affordable and effective oncology treatments to a broad patient population.

Buyer Due Diligence Brief — Evaluating Fresenius Kabi Oncology Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Fresenius Kabi Oncology Limited has a track record of supplying high-quality pharmaceutical products globally. The company's export

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Fresenius Kabi Oncology Limited

How many pharmaceutical products does Fresenius Kabi Oncology Limited export from India?

Fresenius Kabi Oncology Limited exports 16 pharmaceutical products across 3 therapeutic categories. The top exports are Carboplatin ($27.5M), Paclitaxel ($25.1M), Oxaliplatin ($16.6M), Irinotecan ($10.4M), Pemetrexed ($9.0M). Total export value is $117.2M.

What is Fresenius Kabi Oncology Limited's total pharmaceutical export value?

Fresenius Kabi Oncology Limited's total pharmaceutical export value is $117.2M, based on 4,662 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Fresenius Kabi Oncology Limited the #1 Indian exporter?

Fresenius Kabi Oncology Limited is the #1 Indian exporter in 7 products: Carboplatin (38.8% market share), Paclitaxel (30.2% market share), Oxaliplatin (35.7% market share), Pemetrexed (31.1% market share), Docetaxel (21.1% market share), Gemcitabine (14.8% market share), Cisplatin (21.5% market share).

What therapeutic categories does Fresenius Kabi Oncology Limited cover?

Fresenius Kabi Oncology Limited exports across 3 therapeutic categories. The largest are Oncology (73.4%, 8 products), Advanced Oncology (26.0%, 7 products), Immunosuppressants (0.7%, 1 products).

Get Full Fresenius Kabi Oncology Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.